Reilly Joseph James
Known title: See RemarksCIK: 0002044416
Associated companies
Transaction History
| ARDX | ▼ Sell | Open Market | 2,872 | $11K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,110 | $4K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,683 | $17K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,036 | $6K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 4,387 | $26K | 2/20/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2 | $11 | 2/20/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 602 | $3K | 2/20/2026 | View on chart |
| ARDX | ▲ Buy | Grant | 46,200 | $0 | 1/23/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 11,086 | $61K | 11/21/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.